BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 10351671)

  • 1. Does the UK National Health Service need a fourth hurdle for pharmaceutical reimbursement to encourage the more efficient prescribing of pharmaceuticals?
    Freemantle N
    Health Policy; 1999 Mar; 46(3):255-65. PubMed ID: 10351671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The management of the cost and utilisation of pharmaceuticals in the United Kingdom.
    Burstall ML
    Health Policy; 1997 Sep; 41 Suppl():S27-43. PubMed ID: 10174472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The UK pharmaceutical market. An overview.
    Towse A
    Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost and utilisation of pharmaceuticals in Sweden.
    Ljungkvist MO; Andersson D; Gunnarsson B
    Health Policy; 1997 Sep; 41 Suppl():S55-69. PubMed ID: 10174474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UK budgetary systems and new health-care technologies.
    McGuire A; Litt M
    Value Health; 2003; 6 Suppl 1():S64-73. PubMed ID: 12846927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of economic evaluation in the pricing and reimbursement of medicines.
    Drummond M; Jönsson B; Rutten F
    Health Policy; 1997 Jun; 40(3):199-215. PubMed ID: 10168752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OFT, VBP: QED?
    Claxton K
    Health Econ; 2007 Jun; 16(6):545-58. PubMed ID: 17535009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug price reform in the UK: debunking the myths.
    Thornton S
    Health Econ; 2007 Oct; 16(10):981-92. PubMed ID: 17853505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The way to economic prescribing.
    Ryan M; Yule B
    Health Policy; 1993 Sep; 25(1-2):25-38. PubMed ID: 10129157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The National Health Service pharmaceuticals market. Recent and prospective reforms.
    Green DG
    Pharmacoeconomics; 1994; 6 Suppl 1():11-4. PubMed ID: 10155580
    [No Abstract]   [Full Text] [Related]  

  • 12. Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.
    Parkinson B; Sermet C; Clement F; Crausaz S; Godman B; Garner S; Choudhury M; Pearson SA; Viney R; Lopert R; Elshaug AG
    Pharmacoeconomics; 2015 Sep; 33(9):905-24. PubMed ID: 26048353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmaceutical cost containment and innovation in the United States.
    Kane NM
    Health Policy; 1997 Sep; 41 Suppl():S71-89. PubMed ID: 10174475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription drug payment policy: past, present, and future.
    Gondek K
    Health Care Financ Rev; 1994; 15(3):1-7. PubMed ID: 10137792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between increasing prescription charges and consumption in groups not exempt from charges.
    Birch S
    J R Coll Gen Pract; 1986 Apr; 36(285):154-6. PubMed ID: 3735198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient charges and the utilisation of NHS prescription medicines: some estimates using a cointegration procedure.
    Hughes D; McGuire A
    Health Econ; 1995; 4(3):213-20. PubMed ID: 7550771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom.
    Gross DJ; Ratner J; Perez J; Glavin SL
    Health Care Financ Rev; 1994; 15(3):127-40. PubMed ID: 10137794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.